Poder, A.; Oberije, J.; Meyer, J.; Heymer, P.; Molrine, D.; Versage, E.; Isakov, L.; Zhang, Q.; Hohenboken, M.
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age. Vaccines 2023, 11, 1528.
https://doi.org/10.3390/vaccines11101528
AMA Style
Poder A, Oberije J, Meyer J, Heymer P, Molrine D, Versage E, Isakov L, Zhang Q, Hohenboken M.
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age. Vaccines. 2023; 11(10):1528.
https://doi.org/10.3390/vaccines11101528
Chicago/Turabian Style
Poder, Airi, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine, Eve Versage, Leah Isakov, Qiuhong Zhang, and Matthew Hohenboken.
2023. "Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age" Vaccines 11, no. 10: 1528.
https://doi.org/10.3390/vaccines11101528
APA Style
Poder, A., Oberije, J., Meyer, J., Heymer, P., Molrine, D., Versage, E., Isakov, L., Zhang, Q., & Hohenboken, M.
(2023). Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age. Vaccines, 11(10), 1528.
https://doi.org/10.3390/vaccines11101528
